Mouse Study Suggests Viral Infections May Contribute to Parkinson’s Disease Development

Researchers in the United States have developed a new mouse model that strengthens the evidence that viral infections may contribute to the development of Parkinson's disease. The research provides a new way to investigate how virus-induced brain damage could later progress into long-term movement disorders.

The team at Texas A&M University used Theiler's murine encephalomyelitis virus (TMEV), a virus that naturally infects mice. When introduced into a key region of the brain, the virus selectively destroyed dopamine-producing neurons similar to those lost in people with Parkinson's disease.

Virus Leaves Lasting Damage in the Brain

The researchers observed two key effects in the infected mice. The virus successfully targeted and destroyed dopaminergic neurons, and the animals subsequently developed persistent motor impairments that continued long after the infection itself had resolved.

Over a period of 20 weeks, the mice underwent a series of movement and gait assessments designed to detect Parkinson's-like symptoms. Even after the virus was no longer detectable, the animals continued to show impaired coordination and abnormal walking patterns.

These findings suggest that a relatively short-lived viral infection targeting vulnerable brain cells can leave lasting neurological damage. The researchers propose that a similar process could help set the stage for Parkinson's disease in people who also have other genetic or environmental risk factors.

Beyond Toxin and Genetic Models

Most existing Parkinson's disease models rely on toxins or genetic manipulation to destroy neurons in the substantia nigra, the brain region responsible for producing dopamine and supporting motor control. Although these models have been highly valuable, they may not fully capture the complex biological processes involved in the development of Parkinson's disease in humans.

Lead researcher Candice Brinkmeyer-Langford notes that not everyone exposed to industrial chemicals or pesticides later develops Parkinson's disease. This observation suggests that current experimental models do not account for all of the biological pathways that may contribute to the disorder under real-world conditions.

The new viral model offers an alternative mechanism for producing similar neuronal loss, allowing researchers to investigate how inflammation, immune responses, and viral activity interact with the brain's underlying vulnerability. It may also help explain why only some individuals exposed to infections or environmental toxins eventually develop neurodegeneration.

Viruses and the Risk of Neurodegeneration

Evidence linking viral infections to neurodegenerative diseases has been accumulating for decades, from observations following the 1918 influenza pandemic to more recent research examining the potential neurological consequences of COVID-19. Certain viruses, including Epstein-Barr virus, have already been associated with an increased risk of multiple sclerosis and several forms of cancer.

Brinkmeyer-Langford points out that the same virus can produce very different outcomes depending on an individual's genetic background. In Parkinson's disease, viral damage to dopamine-producing neurons may represent one of several contributing factors, alongside aging, inherited susceptibility, and exposure to environmental toxins.

Importantly, TMEV does not infect humans, meaning the findings do not indicate that this virus poses a direct threat to people. Instead, the virus serves as a controlled experimental tool that allows researchers to generate Parkinson's-like brain damage and study how those injuries lead to long-term neurological symptoms.

Implications for Future Treatments

Parkinson's disease affects more than 10 million people worldwide and is the second most common neurodegenerative disorder after dementia. As populations continue to age, the global number of cases is expected to increase substantially in the coming decades.

By providing a model that more closely reflects how real-world viral infections might influence the risk of Parkinson's disease, the TMEV model could help guide future approaches to prevention and treatment. These approaches may include antiviral therapies, vaccines, or interventions designed to protect vulnerable neurons during or after viral infection.

The researchers hope that future studies using this model will identify which genetic profiles and environmental exposures interact most strongly with virus-induced brain injury. Such insights could ultimately contribute to earlier diagnosis and more personalized care for people at elevated risk of Parkinson's disease.

The findings, published in Brain, Behavior, and Immunity – Health, add further support to the hypothesis that viral infections should be considered potential contributors to neurodegenerative diseases, even when the initial illness appears to have fully resolved.